Search
fluoropyrimidine S-1; tegafur/5-chloro-2,4-dihydroxypyridine/potassium oxonate
Indications:
- used in combination with chemoradiation for treatment of esophageal cancer
Adverse effects:
- esophagitis (17%), pneumonitis, & thrombocytopenia, leukopenia (13%)
Mechanism of action:
- designed to have enhanced cancer activity & less toxicity than fluorouracil + cisplatin
General
antineoplastic combination (combination chemotherapy)
References
- Ji Y, Du X, Zhu W et al
Efficacy of Concurrent Chemoradiotherapy With S-1 vs Radiotherapy Alone
for Older Patients With Esophageal Cancer. A Multicenter Randomized Phase 3
Clinical Trial.
JAMA Oncol. Published online August 5, 2021
PMID: 34351356
https://jamanetwork.com/journals/jamaoncology/fullarticle/2782741
- Eads JR, Haller DG
Primary Chemoradiotherapy for Older Patients With Esophageal Cancer.
JAMA Oncol. Published online August 5, 2021
PMID: 34351378
https://jamanetwork.com/journals/jamaoncology/fullarticle/2782745